Literature DB >> 27357541

Glucose Oncometabolism of Esophageal Cancer.

Jason S Hochwald, Jianliang Zhang1.   

Abstract

Metabolic reprograming contributes to esophageal tumorigenesis. A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC. Current achievements in the field of EC glucose metabolism have been critically reviewed to address several fundamental questions. These include: 1) the association of abnormal glucose metabolism and EC risk; 2) alterations of genes and/or proteins that contribute to glucose oncometabolism in EC; 3) signal transduction pathways that promote EC consumption of glucose; and, 4) targeting the glycolytic element or the EC dependency on excessive glucose consumption to prevent growth of EC caused by different genomic changes. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Tumor metabolism; altered genes; glucose dependence; glycolysis; inhibitors; mitochondria

Mesh:

Substances:

Year:  2017        PMID: 27357541     DOI: 10.2174/1871520616666160627092716

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  6 in total

1.  Identification of a RNA-Seq Based 8-Long Non-Coding RNA Signature Predicting Survival in Esophageal Cancer.

Authors:  Qiaowei Fan; Bingrong Liu
Journal:  Med Sci Monit       Date:  2016-12-28

Review 2.  Metabolomics and the Multi-Omics View of Cancer.

Authors:  David Wishart
Journal:  Metabolites       Date:  2022-02-07

3.  LINC00114 stimulates growth and glycolysis of esophageal cancer cells by recruiting EZH2 to enhance H3K27me3 of DLC1.

Authors:  Jianzhang Qin; Yishuai Li; Zhe Li; Xuebo Qin; Xuetao Zhou; Hao Zhang; Shujun Li
Journal:  Clin Epigenetics       Date:  2022-04-12       Impact factor: 6.551

4.  miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development.

Authors:  Wei Bian; Yishuai Li; Haiyong Zhu; Shaolin Gao; Ren Niu; Chuan Wang; Hao Zhang; Xuebo Qin; Shujun Li
Journal:  Thorac Cancer       Date:  2021-04-01       Impact factor: 3.500

5.  Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.

Authors:  Dilireba Bolidong; Takahiro Domoto; Masahiro Uehara; Hemragul Sabit; Tomoyuki Okumura; Yoshio Endo; Mitsutoshi Nakada; Itasu Ninomiya; Tomoharu Miyashita; Richard W Wong; Toshinari Minamoto
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

6.  Glycolysis Changes the Microenvironment and Therapeutic Response Under the Driver of Gene Mutation in Esophageal Adenocarcinoma.

Authors:  Lei Zhu; Fugui Yang; Xinrui Li; Qinchuan Li; Chunlong Zhong
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.